Prevalence and Description of FIRE (Food Induced Immediate Response of the Esophagus) in the Pediatric Population With Eosinophilic Esophagitis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

40 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-07-01

Study Completion Date

2026-05-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A new clinical entity of eosinophilic esophagitis, Food Induced Immediate Response of the Esophagus or FIRE, has been described since 2020. Diagnostic criteria are not clearly established. Specific questioning is necessary for differential diagnosis, such as the oro-pharyngeal syndrome notably described in pollinics, or a mechanical blockage strictly speaking linked to esophagitis. The aim is to obtain epidemiological data on this entity.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Eosinophilic Esophagitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

eosinophilic esophagitis

questionnary

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients over 6 and under 18 years of age at the time of inclusion
* Follow-up in the allergology unit of Angers University Hospital for eosinophilic esophagitis

Exclusion Criteria

* Patients or legal representative with severe communication or language comprehension difficulties
* Patients or legal representatives objecting to study participation

Minimum Eligible Age

6 Years

Maximum Eligible Age

17 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Anne HOPPE

Role: PRINCIPAL_INVESTIGATOR

University Hospital of Angers

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

HOPPE Anne

Angers, , France

Site Status RECRUITING

CHU Lille

Lille, , France

Site Status NOT_YET_RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Anne HOPPE, MD

Role: CONTACT

Phone: 241353637

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Madeleine AUMAR

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CHU Angers

Identifier Type: OTHER

Identifier Source: secondary_id

49RC25_0086

Identifier Type: -

Identifier Source: org_study_id